HansBiomed Corporation (042520) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HansBiomed Corporation (042520) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.21 Billion ≈ $817.15K USD) by net assets (₩33.89 Billion ≈ $22.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HansBiomed Corporation (042520) net asset quality to measure how much of total assets are equity-financed.
HansBiomed Corporation - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how HansBiomed Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HansBiomed Corporation cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
HansBiomed Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HansBiomed Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fu Yu Property Co Ltd
TWO:4907
|
0.079x |
|
Thai Rayon Public Company Limited
BK:TR
|
-0.018x |
|
PHX Minerals Inc
NYSE:PHX
|
0.034x |
|
Mendelson Infrastructures and Industries Ltd
TA:MNIN
|
0.061x |
|
Central Hydropower JSC
VN:CHP
|
0.085x |
|
Bank Artha Graha Internasional
JK:INPC
|
0.010x |
|
AB Klaipedos nafta
F:XIC
|
-0.143x |
|
Lifecore Biomedical Inc.
NASDAQ:LFCR
|
0.226x |
Annual Cash Flow Conversion Efficiency for HansBiomed Corporation (2012–2025)
The table below shows the annual cash flow conversion efficiency of HansBiomed Corporation from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see HansBiomed Corporation (042520) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | ₩33.89 Billion ≈ $22.96 Million |
₩318.34 Million ≈ $215.73K |
0.009x | -64.14% |
| 2024-09-30 | ₩67.12 Billion ≈ $45.49 Million |
₩1.76 Billion ≈ $1.19 Million |
0.026x | +135.06% |
| 2023-09-30 | ₩49.95 Billion ≈ $33.85 Million |
₩-3.73 Billion ≈ $-2.53 Million |
-0.075x | +20.13% |
| 2022-09-30 | ₩45.63 Billion ≈ $30.93 Million |
₩-4.27 Billion ≈ $-2.89 Million |
-0.094x | +71.60% |
| 2021-09-30 | ₩44.45 Billion ≈ $30.12 Million |
₩-14.64 Billion ≈ $-9.92 Million |
-0.329x | -445.66% |
| 2020-09-30 | ₩60.34 Billion ≈ $40.89 Million |
₩5.75 Billion ≈ $3.90 Million |
0.095x | +3.88% |
| 2019-09-30 | ₩84.07 Billion ≈ $56.97 Million |
₩7.71 Billion ≈ $5.23 Million |
0.092x | +15.14% |
| 2018-09-30 | ₩65.30 Billion ≈ $44.26 Million |
₩5.20 Billion ≈ $3.53 Million |
0.080x | -23.50% |
| 2017-09-30 | ₩53.73 Billion ≈ $36.41 Million |
₩5.60 Billion ≈ $3.79 Million |
0.104x | +1642.90% |
| 2016-09-30 | ₩46.82 Billion ≈ $31.73 Million |
₩-316.10 Million ≈ $-214.22K |
-0.007x | -108.41% |
| 2015-09-30 | ₩43.16 Billion ≈ $29.25 Million |
₩3.47 Billion ≈ $2.35 Million |
0.080x | +53.45% |
| 2014-09-30 | ₩39.39 Billion ≈ $26.69 Million |
₩2.06 Billion ≈ $1.40 Million |
0.052x | -34.24% |
| 2013-09-30 | ₩29.31 Billion ≈ $19.86 Million |
₩2.33 Billion ≈ $1.58 Million |
0.080x | +27.45% |
| 2012-09-30 | ₩24.04 Billion ≈ $16.29 Million |
₩1.50 Billion ≈ $1.02 Million |
0.062x | -- |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more